FDA Hits Snooze Button on Neurocrine's Sleep Drug

Law360, New York (September 5, 2006, 12:00 AM EDT) -- Further clouding the future of insomnia drug Indiplon, Neurocrine Biosciences Inc. said on Tuesday that the FDA has asked it to reanalyze safety and efficacy data because of issues raised in an initial review.

The FDA initially approved two low-dose versions of Indiplon, but issued a non-approval letter for the higher and longer lasting 15-mg dose.

Indiplon is a drug that acts on a specific site of the GABA-A receptor in the brain believed to be responsible for promoting sleep.

The original application for Indiplon was...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.